What are the details of the TACO‑PE (Tenecteplase versus Alteplase in Massive Pulmonary Embolism) trial, including patient criteria, thrombolytic dosing regimens, efficacy outcomes, and major bleeding rates?

TACO-PE Trial: Tenecteplase versus Alteplase in Massive Pulmonary Embolism

The TACO-PE trial found that tenecteplase was associated with significantly higher major bleeding rates (17%) compared to alteplase (5%) in massive PE patients, with concerningly high mortality rates in both groups (83% vs 75%), suggesting alteplase remains the safer thrombolytic choice for massive PE. 1

Study Design and Patient Population

The TACO-PE study was a retrospective, observational cohort study conducted at a single institution that transitioned from alteplase to tenecteplase as the formulary thrombolytic in October 2022. 1 The trial included:

• 44 adult patients total (20 in alteplase cohort, 24 in tenecteplase cohort) 1
• Inclusion criteria: Adults who received systemic thrombolysis for massive pulmonary embolism 1
• Study objective: Compare bleeding incidence between tenecteplase and alteplase in massive PE, as previous literature was unclear regarding tenecteplase's bleed risk in this specific population 1

Thrombolytic Dosing Regimens

While the TACO-PE trial itself does not specify exact dosing used, standard dosing for PE thrombolysis based on current guidelines includes:

• Alteplase: 100 mg administered as a continuous infusion over 2 hours 2, 3, 4
• Tenecteplase: Weight-based single IV bolus (30 mg for <60 kg; 35 mg for 60-69 kg; 40 mg for 70-79 kg; 45 mg for 80-89 kg; 50 mg for ≥90 kg) 5, 6

The key practical difference is that tenecteplase is administered as a single bolus versus alteplase's 2-hour infusion, which theoretically offers ease of administration. 5, 6

Primary Efficacy and Safety Outcomes

Major Bleeding Rates (Primary Outcome)

The TACO-PE trial revealed a concerning 3.4-fold increase in major bleeding with tenecteplase:

• Tenecteplase: 17% major bleeding rate (defined by ISTH criteria) 1
• Alteplase: 5% major bleeding rate 1

This finding contradicts data from acute myocardial infarction trials where tenecteplase showed reduced noncerebral bleeding compared to alteplase. 5, 6 The higher bleeding risk in PE patients may reflect differences in disease pathophysiology, patient acuity, or concurrent anticoagulation management.

Intracranial Hemorrhage

• One patient in the tenecteplase cohort experienced symptomatic intracranial hemorrhage 1
• No symptomatic ICH occurred in the alteplase group 1

This is particularly concerning given that ICH represents the most devastating bleeding complication of thrombolysis, with the PEITHO trial in intermediate-risk PE showing 2.0% ICH rate with tenecteplase versus 0.2% with placebo. 7

Mortality Outcomes

Both groups demonstrated extremely high mortality rates, reflecting the severity of massive PE:

• Tenecteplase: 83% in-hospital mortality 1
• Alteplase: 75% in-hospital mortality 1

These mortality rates are substantially higher than typically reported for massive PE with thrombolysis, suggesting either exceptionally high-risk patients or potential selection bias in this retrospective cohort. For context, the PEITHO trial in intermediate-risk PE showed only 2.4% mortality at 7 days with tenecteplase. 8

Additional Safety Outcomes

• Two patients in the tenecteplase cohort required massive transfusion protocol initiation 1
• Reversal agent administration rates were tracked but specific numbers not detailed in the abstract 1

Critical Limitations and Clinical Context

Study Limitations

The TACO-PE trial has significant methodological constraints:

• Small sample size (n=44) limits statistical power and generalizability 1
• Retrospective design introduces selection bias and confounding 1
• Single-center study may not reflect broader practice patterns 1
• Observational cohort without randomization means baseline characteristics may differ between groups 1

Contradictory Evidence from Other Studies

A 2025 multicenter retrospective study (n=larger cohort) found different results, showing alteplase had the lowest major bleeding risk (10.9%) compared to tenecteplase (31.1%, P=0.004) and ultrasound-facilitated catheter-directed thrombolysis (21.4%, P=0.03) in intermediate-high risk PE. 9 After propensity matching, tenecteplase showed higher bleeding rates (P=0.13) while US-CDT had significantly higher complications (P=0.04). 9

However, a 2025 prospective observational study with historical controls (n=54) found no difference in bleeding outcomes between tenecteplase and alteplase for PE or cardiac arrest with suspected PE, with any bleeding at 12% vs 13.8% (P=1.0) and major bleeding at 8.0% vs 6.9% (P=1.0). 10

Current Guideline Recommendations

The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN PE Guideline provides the most recent comprehensive recommendations for acute PE management, introducing new clinical categories for severity classification and evidence-based therapeutic decision-making. 11 This guideline addresses pharmacological therapies including thrombolysis for both intermediate and high-risk PE. 11

For massive/high-risk PE (sustained hypotension >15 minutes or vasopressor requirement):

• Systemic thrombolysis is recommended as standard therapy 7
• Alteplase 100 mg over 2 hours remains the FDA-recommended regimen 2, 3
• Catheter-directed therapy is an alternative in appropriately selected patients 7

The 2025 ACC/AHA/ACEP guidelines for acute coronary syndromes note that tenecteplase and alteplase were equivalent for 30-day mortality in AMI, but tenecteplase was associated with reduced noncerebral bleeding in that population. 5, 6 However, this cardiovascular benefit may not translate to PE patients.

Clinical Algorithm for Thrombolytic Selection in Massive PE

Based on the totality of evidence, the following approach is recommended:

1. First-line choice: Alteplase 100 mg IV over 2 hours 2, 3

   • Established safety profile in PE populations
   • Lower bleeding risk demonstrated in TACO-PE and supporting studies 1, 9
   • FDA-approved dosing with extensive clinical experience 12

2. Consider tenecteplase only when:

   • Alteplase is unavailable
   • Single bolus administration is critically important (e.g., cardiac arrest scenario requiring rapid dosing)
   • Patient has no additional bleeding risk factors
   • Acknowledge the potentially higher bleeding risk 1, 9

3. Absolute contraindications to any thrombolytic (apply to both agents): 5, 6, 4

   • Any prior intracranial hemorrhage
   • Known structural cerebral vascular lesion
   • Known malignant intracranial neoplasm
   • Ischemic stroke within 3 months
   • Suspected aortic dissection
   • Active bleeding or bleeding diathesis
   • Significant closed-head or facial trauma within 3 months
   • Intracranial or intraspinal surgery within 2 months
   • Severe uncontrolled hypertension (SBP >180 mm Hg or DBP >110 mm Hg unresponsive to therapy)

4. Alternative interventions when thrombolysis contraindicated:

   • Catheter-directed therapy (mechanical thrombectomy or pharmacologic) 7
   • Surgical embolectomy 7
   • ECMO as rescue therapy in refractory cardiogenic shock 7

Common Pitfalls to Avoid

• Do not delay thrombolysis in massive PE to obtain imaging confirmation if clinical diagnosis is highly probable—mortality benefit is time-dependent, with greatest benefit within 48 hours of symptom onset 4
• Do not assume tenecteplase's ease of administration (single bolus) outweighs the potential increased bleeding risk in PE patients, unlike in AMI populations 1, 9
• Do not withhold thrombolysis in life-threatening PE due to relative contraindications—in cardiac arrest or profound shock from PE, contraindications should be considered advisory rather than absolute 3
• Do not use systemic thrombolysis in intermediate-risk PE without careful risk-benefit assessment—the PEITHO trial showed increased major bleeding (6.3% vs 1.2%) and ICH (2.0% vs 0.2%) with only modest reduction in hemodynamic decompensation 7